| 000 | 01356 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250517213344.0 | ||
| 264 | 0 | _c20190329 | |
| 008 | 201903s 0 0 eng d | ||
| 022 | _a1440-1746 | ||
| 024 | 7 |
_a10.1111/jgh.14136 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHamoir, C | |
| 245 | 0 | 0 |
_aHepatobiliary and Pancreatic: Nivolumab-related cholangiopathy. _h[electronic resource] |
| 260 |
_bJournal of gastroenterology and hepatology _cOct 2018 |
||
| 300 |
_a1695 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xadverse effects |
| 650 | 0 | 4 |
_aBile Ducts, Intrahepatic _xdiagnostic imaging |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xtherapy |
| 650 | 0 | 4 | _aCholangiopancreatography, Magnetic Resonance |
| 650 | 0 | 4 |
_aCholangitis _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xadverse effects |
| 650 | 0 | 4 |
_aLung Neoplasms _xtherapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNivolumab _xadverse effects |
| 700 | 1 | _ade Vos, M | |
| 700 | 1 | _aClinckart, F | |
| 700 | 1 | _aNicaise, G | |
| 700 | 1 | _aKomuta, M | |
| 700 | 1 | _aLanthier, N | |
| 773 | 0 |
_tJournal of gastroenterology and hepatology _gvol. 33 _gno. 10 _gp. 1695 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/jgh.14136 _zAvailable from publisher's website |
| 999 |
_c28338831 _d28338831 |
||